Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyGarenoxacin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Garenoxacin
- Accession Number
- DB06160
- Type
- Small Molecule
- Groups
- Investigational
- Description
Garenoxacin (INN) is a quinolone antibiotic undergoing regulatory review for the treatment of gram-positive and gram-negative bacterial infections. [Wikipedia]
- Structure
Structure for DB06160 (Garenoxacin)
- Synonyms
- desquinolone
- External IDs
- T-3811
- Product Ingredients
Ingredient UNII CAS InChI Key Garenoxacin Mesylate OXI6EF55FR 223652-90-2 IGTHEWGRXUAFKF-NVJADKKVSA-N - Categories
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Antineoplastic Agents
- Cytochrome P-450 CYP1A2 Inhibitors
- Enzyme Inhibitors
- Fluoroquinolones
- Moderate Risk QTc-Prolonging Agents
- QTc Prolonging Agents
- Quinolines
- Quinolones
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- UNII
- V72H9867WB
- CAS number
- 194804-75-6
- Weight
- Average: 426.42
Monoisotopic: 426.139113458 - Chemical Formula
- C23H20F2N2O4
- InChI Key
- NJDRXTDGYFKORP-LLVKDONJSA-N
- InChI
- InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1
- IUPAC Name
- 1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- SMILES
- C[C@H]1NCC2=CC(=CC=C12)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1OC(F)F)C(O)=O
Pharmacology
- Indication
Investigated for use/treatment in bacterial infection.
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may increase the neuroexcitatory activities of Garenoxacin. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Garenoxacin. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Garenoxacin. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when 5-androstenedione is combined with Garenoxacin. Experimental, Illicit Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Garenoxacin. Approved, Investigational Aceclofenac Aceclofenac may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Acemetacin Acemetacin may increase the neuroexcitatory activities of Garenoxacin. Approved, Experimental, Investigational Acenocoumarol Garenoxacin may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Garenoxacin. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Garenoxacin. Experimental Acetylsalicylic acid Acetylsalicylic acid may increase the neuroexcitatory activities of Garenoxacin. Approved, Vet Approved Adapalene Adapalene may increase the neuroexcitatory activities of Garenoxacin. Approved Albiglutide Garenoxacin may increase the hypoglycemic activities of Albiglutide. Approved Alclofenac Alclofenac may increase the neuroexcitatory activities of Garenoxacin. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Alclometasone is combined with Garenoxacin. Approved Aldosterone The risk or severity of adverse effects can be increased when Aldosterone is combined with Garenoxacin. Experimental, Investigational Almasilate Almasilate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Alminoprofen Alminoprofen may increase the neuroexcitatory activities of Garenoxacin. Experimental Alogliptin Garenoxacin may increase the hypoglycemic activities of Alogliptin. Approved Aloglutamol Aloglutamol can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Aluminium Aluminium can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Aluminium acetoacetate Aluminium acetoacetate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminium glycinate Aluminium glycinate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Ambroxol acefyllinate The metabolism of Ambroxol acefyllinate can be decreased when combined with Garenoxacin. Experimental, Investigational Amcinonide The risk or severity of adverse effects can be increased when Amcinonide is combined with Garenoxacin. Approved Aminophylline The metabolism of Aminophylline can be decreased when combined with Garenoxacin. Approved Amiodarone The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Amiodarone. Approved, Investigational Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Garenoxacin. Approved, Investigational, Withdrawn Andrographolide Andrographolide may increase the neuroexcitatory activities of Garenoxacin. Investigational Androstenedione The risk or severity of adverse effects can be increased when Androstenedione is combined with Garenoxacin. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Anecortave is combined with Garenoxacin. Investigational anecortave acetate The risk or severity of adverse effects can be increased when anecortave acetate is combined with Garenoxacin. Investigational Anisodamine Anisodamine may increase the neuroexcitatory activities of Garenoxacin. Investigational Antipyrine Antipyrine may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Apocynin Apocynin may increase the neuroexcitatory activities of Garenoxacin. Investigational Apremilast Apremilast may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Atamestane The risk or severity of adverse effects can be increased when Atamestane is combined with Garenoxacin. Investigational Azapropazone Azapropazone may increase the neuroexcitatory activities of Garenoxacin. Withdrawn Azelastine Azelastine may increase the neuroexcitatory activities of Garenoxacin. Approved Balsalazide Balsalazide may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Garenoxacin. Investigational Beclomethasone dipropionate The risk or severity of tendinopathy can be increased when Beclomethasone dipropionate is combined with Garenoxacin. Approved, Investigational Bendazac Bendazac may increase the neuroexcitatory activities of Garenoxacin. Experimental Benorilate Benorilate may increase the neuroexcitatory activities of Garenoxacin. Experimental Benoxaprofen Benoxaprofen may increase the neuroexcitatory activities of Garenoxacin. Withdrawn Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Garenoxacin. Approved Benzydamine Benzydamine may increase the neuroexcitatory activities of Garenoxacin. Approved Bepridil The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Bepridil. Approved, Withdrawn Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Garenoxacin. Approved, Vet Approved Bevacizumab Bevacizumab may increase the cardiotoxic activities of Garenoxacin. Approved, Investigational Bevonium Bevonium may increase the neuroexcitatory activities of Garenoxacin. Experimental Bismuth subcitrate potassium Bismuth Subcitrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Bismuth subnitrate Bismuth subnitrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Bromfenac Bromfenac may increase the neuroexcitatory activities of Garenoxacin. Approved Bromocriptine Garenoxacin may increase the hypoglycemic activities of Bromocriptine. Approved, Investigational Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Garenoxacin. Approved Bucillamine Bucillamine may increase the neuroexcitatory activities of Garenoxacin. Investigational Budesonide The risk or severity of tendinopathy can be increased when Budesonide is combined with Garenoxacin. Approved Bufexamac Bufexamac may increase the neuroexcitatory activities of Garenoxacin. Approved, Experimental Bumadizone Bumadizone may increase the neuroexcitatory activities of Garenoxacin. Experimental Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Garenoxacin. Approved Caffeine The metabolism of Caffeine can be decreased when combined with Garenoxacin. Approved Calcium Acetate Calcium Acetate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Calcium Carbonate Calcium Carbonate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Calcium Chloride Calcium Chloride can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium Citrate Calcium Citrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium glubionate Calcium glubionate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium Gluceptate Calcium Gluceptate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium gluconate Calcium gluconate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Calcium lactate Calcium lactate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Calcium lactate gluconate Calcium lactate gluconate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Calcium levulinate Calcium levulinate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Calcium pangamate Calcium pangamate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Calcium Phosphate Calcium Phosphate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium silicate Calcium silicate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Canagliflozin Garenoxacin may increase the hypoglycemic activities of Canagliflozin. Approved Carbaspirin calcium Carbaspirin calcium may increase the neuroexcitatory activities of Garenoxacin. Experimental, Investigational Carprofen Carprofen may increase the neuroexcitatory activities of Garenoxacin. Approved, Vet Approved, Withdrawn Casein Casein can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Castanospermine Castanospermine may increase the neuroexcitatory activities of Garenoxacin. Experimental Celecoxib Celecoxib may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Garenoxacin. Approved Chloroquine Chloroquine may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational, Vet Approved Chlorphenamine The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Chlorphenamine. Approved Chlorpropamide Garenoxacin may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Choline magnesium trisalicylate Choline magnesium trisalicylate may increase the neuroexcitatory activities of Garenoxacin. Approved Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Garenoxacin. Approved, Investigational Cinnarizine The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Cinnarizine. Approved, Investigational Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Garenoxacin. Approved, Investigational Clemastine The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Clemastine. Approved, Investigational Clobetasol The risk or severity of adverse effects can be increased when Clobetasol is combined with Garenoxacin. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Garenoxacin. Approved Clobetasone The risk or severity of adverse effects can be increased when Clobetasone is combined with Garenoxacin. Approved Clocortolone The risk or severity of adverse effects can be increased when Clocortolone is combined with Garenoxacin. Approved Clonixin Clonixin may increase the neuroexcitatory activities of Garenoxacin. Approved Clorindione Garenoxacin may increase the anticoagulant activities of Clorindione. Experimental Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Garenoxacin. Investigational Corticosterone The risk or severity of adverse effects can be increased when Corticosterone is combined with Garenoxacin. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Garenoxacin. Approved, Investigational Curcumin Curcumin may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Garenoxacin. Approved, Investigational Cymarin Cymarin may decrease the cardiotoxic activities of Garenoxacin. Experimental Dapagliflozin The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Garenoxacin. Approved Deflazacort The risk or severity of adverse effects can be increased when Deflazacort is combined with Garenoxacin. Approved, Investigational Delamanid Garenoxacin may increase the QTc-prolonging activities of Delamanid. Approved, Investigational Deslanoside Deslanoside may decrease the cardiotoxic activities of Garenoxacin. Approved Desonide The risk or severity of adverse effects can be increased when Desonide is combined with Garenoxacin. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Garenoxacin. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Garenoxacin. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Garenoxacin. Experimental, Vet Approved Dexamethasone The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Garenoxacin. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Garenoxacin. Vet Approved Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Garenoxacin. Approved Diclofenac Diclofenac may increase the neuroexcitatory activities of Garenoxacin. Approved, Vet Approved Dicoumarol Garenoxacin may increase the anticoagulant activities of Dicoumarol. Approved Didanosine The serum concentration of Didanosine can be decreased when it is combined with Garenoxacin. Approved Difenpiramide Difenpiramide may increase the neuroexcitatory activities of Garenoxacin. Experimental Diflorasone The risk or severity of adverse effects can be increased when Diflorasone is combined with Garenoxacin. Approved Diflunisal Diflunisal may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Difluocortolone is combined with Garenoxacin. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Difluprednate is combined with Garenoxacin. Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Garenoxacin. Approved, Investigational Digoxin Digoxin may decrease the cardiotoxic activities of Garenoxacin. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Garenoxacin. Approved Dimenhydrinate The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Dimenhydrinate. Approved Diphenadione Garenoxacin may increase the anticoagulant activities of Diphenadione. Experimental Diphenhydramine The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Garenoxacin. Approved, Investigational Disopyramide Garenoxacin may increase the hypoglycemic activities of Disopyramide. Approved Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Garenoxacin. Approved, Investigational Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Garenoxacin. Approved, Vet Approved Droxicam Droxicam may increase the neuroexcitatory activities of Garenoxacin. Withdrawn Dulaglutide Garenoxacin may increase the hypoglycemic activities of Dulaglutide. Approved, Investigational Duvelisib Duvelisib may increase the neuroexcitatory activities of Garenoxacin. Investigational Dyphylline The metabolism of Dyphylline can be decreased when combined with Garenoxacin. Approved E-6201 E-6201 may increase the neuroexcitatory activities of Garenoxacin. Investigational Empagliflozin Garenoxacin may increase the hypoglycemic activities of Empagliflozin. Approved Epirizole Epirizole may increase the neuroexcitatory activities of Garenoxacin. Approved Equilenin The risk or severity of adverse effects can be increased when Equilenin is combined with Garenoxacin. Experimental Equilin The risk or severity of adverse effects can be increased when Equilin is combined with Garenoxacin. Approved Estrone The risk or severity of adverse effects can be increased when Estrone is combined with Garenoxacin. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Garenoxacin. Approved Ethenzamide Ethenzamide may increase the neuroexcitatory activities of Garenoxacin. Experimental Ethyl biscoumacetate Garenoxacin may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etodolac Etodolac may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational, Vet Approved Etofenamate Etofenamate may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Etoricoxib Etoricoxib may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Exenatide Garenoxacin may increase the hypoglycemic activities of Exenatide. Approved, Investigational Exisulind Exisulind may increase the neuroexcitatory activities of Garenoxacin. Investigational Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Garenoxacin. Approved Felbinac Felbinac may increase the neuroexcitatory activities of Garenoxacin. Experimental Fenbufen Fenbufen may increase the neuroexcitatory activities of Garenoxacin. Approved Fenoprofen Fenoprofen may increase the neuroexcitatory activities of Garenoxacin. Approved Fentiazac Fentiazac may increase the neuroexcitatory activities of Garenoxacin. Experimental Feprazone Feprazone may increase the neuroexcitatory activities of Garenoxacin. Experimental Ferric Carboxymaltose The serum concentration of Garenoxacin can be decreased when it is combined with Ferric Carboxymaltose. Approved Ferric pyrophosphate The serum concentration of Garenoxacin can be decreased when it is combined with Ferric pyrophosphate. Experimental Ferulic acid Ferulic acid may increase the neuroexcitatory activities of Garenoxacin. Experimental Floctafenine Floctafenine may increase the neuroexcitatory activities of Garenoxacin. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Fluasterone is combined with Garenoxacin. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Garenoxacin. Approved, Investigational Fluindione Garenoxacin may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumethasone The risk or severity of adverse effects can be increased when Flumethasone is combined with Garenoxacin. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Garenoxacin. Approved, Investigational Flunixin Flunixin may increase the neuroexcitatory activities of Garenoxacin. Vet Approved Flunoxaprofen Flunoxaprofen may increase the neuroexcitatory activities of Garenoxacin. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Garenoxacin. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Garenoxacin. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Fluocortolone is combined with Garenoxacin. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Garenoxacin. Approved, Investigational Fluoxetine The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Fluoxetine. Approved, Vet Approved Fluprednidene The risk or severity of adverse effects can be increased when Fluprednidene is combined with Garenoxacin. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Garenoxacin. Approved Flurandrenolide The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Garenoxacin. Approved Flurbiprofen Flurbiprofen may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Fluticasone The risk or severity of adverse effects can be increased when Fluticasone is combined with Garenoxacin. Approved, Experimental, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Garenoxacin. Approved Fluticasone propionate The risk or severity of tendinopathy can be increased when Fluticasone propionate is combined with Garenoxacin. Approved Formestane The risk or severity of adverse effects can be increased when Formestane is combined with Garenoxacin. Approved, Investigational, Withdrawn Ganciclovir The metabolism of Ganciclovir can be decreased when combined with Garenoxacin. Approved, Investigational Gitoformate Gitoformate may decrease the cardiotoxic activities of Garenoxacin. Experimental Gliclazide Garenoxacin may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride The therapeutic efficacy of Glimepiride can be increased when used in combination with Garenoxacin. Approved Glipizide The therapeutic efficacy of Glipizide can be increased when used in combination with Garenoxacin. Approved, Investigational Glyburide The therapeutic efficacy of Glyburide can be increased when used in combination with Garenoxacin. Approved Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Garenoxacin. Approved Guacetisal Guacetisal may increase the neuroexcitatory activities of Garenoxacin. Experimental Halcinonide The risk or severity of adverse effects can be increased when Halcinonide is combined with Garenoxacin. Approved, Investigational, Withdrawn HE3286 The risk or severity of adverse effects can be increased when HE3286 is combined with Garenoxacin. Investigational Higenamine Higenamine may increase the neuroexcitatory activities of Garenoxacin. Investigational Hydrocortisone The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Garenoxacin. Approved, Vet Approved Hydrocortisone acetate The risk or severity of tendinopathy can be increased when Hydrocortisone acetate is combined with Garenoxacin. Approved, Vet Approved Hydrocortisone butyrate The risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Garenoxacin. Approved, Vet Approved Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Garenoxacin. Approved Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Garenoxacin. Approved, Investigational Ibuprofen Ibuprofen may increase the neuroexcitatory activities of Garenoxacin. Approved Ibuproxam Ibuproxam may increase the neuroexcitatory activities of Garenoxacin. Withdrawn Icatibant Icatibant may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Imidazole salicylate Imidazole salicylate may increase the neuroexcitatory activities of Garenoxacin. Experimental Indobufen Indobufen may increase the neuroexcitatory activities of Garenoxacin. Investigational Indomethacin Indomethacin may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Indoprofen Indoprofen may increase the neuroexcitatory activities of Garenoxacin. Withdrawn Insulin Aspart Garenoxacin may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Garenoxacin may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine The therapeutic efficacy of Insulin Glargine can be increased when used in combination with Garenoxacin. Approved Insulin Glulisine Garenoxacin may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human The therapeutic efficacy of Insulin Human can be increased when used in combination with Garenoxacin. Approved, Investigational Insulin Lispro The therapeutic efficacy of Insulin Lispro can be increased when used in combination with Garenoxacin. Approved Iron The serum concentration of Garenoxacin can be decreased when it is combined with Iron. Approved Iron Dextran The serum concentration of Garenoxacin can be decreased when it is combined with Iron Dextran. Approved, Vet Approved Iron saccharate The serum concentration of Garenoxacin can be decreased when it is combined with Iron saccharate. Approved Isoxicam Isoxicam may increase the neuroexcitatory activities of Garenoxacin. Withdrawn Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Garenoxacin. Approved, Investigational Istaroxime The risk or severity of adverse effects can be increased when Istaroxime is combined with Garenoxacin. Investigational Kebuzone Kebuzone may increase the neuroexcitatory activities of Garenoxacin. Experimental Ketoprofen Ketoprofen may increase the neuroexcitatory activities of Garenoxacin. Approved, Vet Approved Ketorolac Ketorolac may increase the neuroexcitatory activities of Garenoxacin. Approved Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Garenoxacin. Experimental Lanthanum carbonate The serum concentration of Garenoxacin can be decreased when it is combined with Lanthanum carbonate. Approved Leflunomide Leflunomide may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Garenoxacin. Approved, Investigational Liraglutide Garenoxacin may increase the hypoglycemic activities of Liraglutide. Approved Lisofylline Lisofylline may increase the neuroexcitatory activities of Garenoxacin. Investigational Lonazolac Lonazolac may increase the neuroexcitatory activities of Garenoxacin. Experimental Loratadine The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Loratadine. Approved, Investigational Lornoxicam Lornoxicam may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Loteprednol The risk or severity of adverse effects can be increased when Loteprednol is combined with Garenoxacin. Approved Loxoprofen Loxoprofen may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Lumiracoxib Lumiracoxib may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Magaldrate Magaldrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium peroxide Magnesium peroxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Magnesium salicylate The serum concentration of Garenoxacin can be decreased when it is combined with Magnesium salicylate. Approved Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium sulfate Magnesium sulfate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Masoprocol Masoprocol may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when ME-609 is combined with Garenoxacin. Investigational Mecasermin Garenoxacin may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Meclofenamic acid Meclofenamic acid may increase the neuroexcitatory activities of Garenoxacin. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Medrysone is combined with Garenoxacin. Approved Mefenamic acid Mefenamic acid may increase the neuroexcitatory activities of Garenoxacin. Approved Melengestrol The risk or severity of adverse effects can be increased when Melengestrol is combined with Garenoxacin. Vet Approved Meloxicam Meloxicam may increase the neuroexcitatory activities of Garenoxacin. Approved, Vet Approved Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Garenoxacin. Approved, Vet Approved Mesalazine Mesalazine may increase the neuroexcitatory activities of Garenoxacin. Approved Metamizole Metamizole may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational, Withdrawn Metformin The therapeutic efficacy of Metformin can be increased when used in combination with Garenoxacin. Approved Methylprednisolone The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Garenoxacin. Approved, Vet Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Garenoxacin. Experimental Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Garenoxacin. Approved, Investigational Mifepristone Garenoxacin may increase the hypoglycemic activities of Mifepristone. Approved, Investigational Miglitol Garenoxacin may increase the hypoglycemic activities of Miglitol. Approved Mizoribine Mizoribine may increase the neuroexcitatory activities of Garenoxacin. Investigational Mofebutazone Mofebutazone may increase the neuroexcitatory activities of Garenoxacin. Experimental Mometasone The risk or severity of adverse effects can be increased when Mometasone is combined with Garenoxacin. Approved, Vet Approved Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Garenoxacin. Approved, Investigational Mycophenolate mofetil Mycophenolate mofetil may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Mycophenolic acid The serum concentration of Mycophenolic acid can be decreased when it is combined with Garenoxacin. Approved Nabumetone Nabumetone may increase the neuroexcitatory activities of Garenoxacin. Approved Nafamostat Nafamostat may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Naftifine Naftifine may increase the neuroexcitatory activities of Garenoxacin. Approved Naproxen Naproxen may increase the neuroexcitatory activities of Garenoxacin. Approved, Vet Approved Nateglinide Garenoxacin may increase the hypoglycemic activities of Nateglinide. Approved, Investigational NCX 1022 The risk or severity of adverse effects can be increased when NCX 1022 is combined with Garenoxacin. Investigational Nepafenac Nepafenac may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Garenoxacin. Approved, Investigational Nifenazone Nifenazone may increase the neuroexcitatory activities of Garenoxacin. Experimental Niflumic Acid Niflumic Acid may increase the neuroexcitatory activities of Garenoxacin. Approved Nimesulide Nimesulide may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational, Withdrawn Nitroaspirin Nitroaspirin may increase the neuroexcitatory activities of Garenoxacin. Investigational Oleandrin Oleandrin may decrease the cardiotoxic activities of Garenoxacin. Experimental, Investigational Oleoyl-estrone The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Garenoxacin. Investigational Olopatadine Olopatadine may increase the neuroexcitatory activities of Garenoxacin. Approved Olsalazine Olsalazine may increase the neuroexcitatory activities of Garenoxacin. Approved Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Garenoxacin. Approved Orgotein Orgotein may increase the neuroexcitatory activities of Garenoxacin. Vet Approved Ouabain Ouabain may decrease the cardiotoxic activities of Garenoxacin. Approved Oxaprozin Oxaprozin may increase the neuroexcitatory activities of Garenoxacin. Approved Oxyphenbutazone Oxyphenbutazone may increase the neuroexcitatory activities of Garenoxacin. Approved, Withdrawn Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Garenoxacin. Approved, Vet Approved Palmidrol Palmidrol may increase the neuroexcitatory activities of Garenoxacin. Experimental, Nutraceutical Paramethasone The risk or severity of adverse effects can be increased when Paramethasone is combined with Garenoxacin. Approved Parecoxib Parecoxib may increase the neuroexcitatory activities of Garenoxacin. Approved Paroxetine The risk or severity of QTc prolongation can be increased when Paroxetine is combined with Garenoxacin. Approved, Investigational Parthenolide Parthenolide may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Pentamidine Garenoxacin may increase the hypoglycemic activities of Pentamidine. Approved, Investigational Peruvoside Peruvoside may decrease the cardiotoxic activities of Garenoxacin. Experimental Phenindione Garenoxacin may increase the anticoagulant activities of Phenindione. Approved, Investigational Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Garenoxacin. Approved Phenprocoumon Garenoxacin may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone Phenylbutazone may increase the neuroexcitatory activities of Garenoxacin. Approved, Vet Approved Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Garenoxacin. Approved Pimecrolimus Pimecrolimus may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Pioglitazone Garenoxacin may increase the hypoglycemic activities of Pioglitazone. Approved, Investigational Pirfenidone Pirfenidone may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Piroxicam Piroxicam may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Pirprofen Pirprofen may increase the neuroexcitatory activities of Garenoxacin. Experimental Pramlintide Garenoxacin may increase the hypoglycemic activities of Pramlintide. Approved, Investigational Pranoprofen Pranoprofen may increase the neuroexcitatory activities of Garenoxacin. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Garenoxacin. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Garenoxacin. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Prednicarbate is combined with Garenoxacin. Approved, Investigational Prednisolone The risk or severity of tendinopathy can be increased when Prednisolone is combined with Garenoxacin. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Garenoxacin. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Pregnenolone is combined with Garenoxacin. Approved, Experimental, Investigational Probenecid The serum concentration of Garenoxacin can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin Proglumetacin may increase the neuroexcitatory activities of Garenoxacin. Experimental Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Garenoxacin. Approved, Investigational Propacetamol Propacetamol may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Propafenone The risk or severity of QTc prolongation can be increased when Propafenone is combined with Garenoxacin. Approved Propyphenazone Propyphenazone may increase the neuroexcitatory activities of Garenoxacin. Experimental Proquazone Proquazone may increase the neuroexcitatory activities of Garenoxacin. Experimental Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Garenoxacin. Experimental PTC299 PTC299 may increase the neuroexcitatory activities of Garenoxacin. Investigational Quetiapine The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Quetiapine. Approved Quinapril Quinapril can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Quinine Garenoxacin may increase the hypoglycemic activities of Quinine. Approved Repaglinide Garenoxacin may increase the hypoglycemic activities of Repaglinide. Approved, Investigational Resveratrol Resveratrol may increase the neuroexcitatory activities of Garenoxacin. Approved, Experimental, Investigational Rimexolone The risk or severity of adverse effects can be increased when Rimexolone is combined with Garenoxacin. Approved Rofecoxib Rofecoxib may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational, Withdrawn Rosiglitazone The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Garenoxacin. Approved, Investigational Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Garenoxacin. Approved, Vet Approved Salicylamide Salicylamide may increase the neuroexcitatory activities of Garenoxacin. Approved Salicylic acid Salicylic acid may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational, Vet Approved Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Garenoxacin. Approved Salsalate Salsalate may increase the neuroexcitatory activities of Garenoxacin. Approved Saxagliptin The therapeutic efficacy of Saxagliptin can be increased when used in combination with Garenoxacin. Approved Semapimod Semapimod may increase the neuroexcitatory activities of Garenoxacin. Investigational Seratrodast Seratrodast may increase the neuroexcitatory activities of Garenoxacin. Approved Serrapeptase Serrapeptase may increase the neuroexcitatory activities of Garenoxacin. Investigational Sevelamer Sevelamer can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Sitagliptin The therapeutic efficacy of Sitagliptin can be increased when used in combination with Garenoxacin. Approved, Investigational Sodium bicarbonate Sodium bicarbonate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved SRT501 SRT501 may increase the neuroexcitatory activities of Garenoxacin. Investigational Strontium ranelate The serum concentration of Garenoxacin can be decreased when it is combined with Strontium ranelate. Approved, Withdrawn Sucralfate The serum concentration of Garenoxacin can be decreased when it is combined with Sucralfate. Approved Sulfadiazine Garenoxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole Garenoxacin may increase the hypoglycemic activities of Sulfamethoxazole. Approved Sulfasalazine Sulfasalazine may increase the neuroexcitatory activities of Garenoxacin. Approved Sulfisoxazole Garenoxacin may increase the hypoglycemic activities of Sulfisoxazole. Approved, Vet Approved Sulindac Sulindac may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Sunitinib Garenoxacin may increase the hypoglycemic activities of Sunitinib. Approved, Investigational Suprofen Suprofen may increase the neuroexcitatory activities of Garenoxacin. Approved, Withdrawn Suxibuzone Suxibuzone may increase the neuroexcitatory activities of Garenoxacin. Experimental Tarenflurbil Tarenflurbil may increase the neuroexcitatory activities of Garenoxacin. Investigational Tenidap Tenidap may increase the neuroexcitatory activities of Garenoxacin. Experimental Tenoxicam Tenoxicam may increase the neuroexcitatory activities of Garenoxacin. Approved Tepoxalin Tepoxalin may increase the neuroexcitatory activities of Garenoxacin. Vet Approved Teriflunomide Teriflunomide may increase the neuroexcitatory activities of Garenoxacin. Approved Terodiline The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Terodiline. Experimental Theophylline The metabolism of Theophylline can be decreased when combined with Garenoxacin. Approved Tiaprofenic acid Tiaprofenic acid may increase the neuroexcitatory activities of Garenoxacin. Approved Tinoridine Tinoridine may increase the neuroexcitatory activities of Garenoxacin. Investigational Tioclomarol Garenoxacin may increase the anticoagulant activities of Tioclomarol. Experimental Tixocortol The risk or severity of adverse effects can be increased when Tixocortol is combined with Garenoxacin. Approved, Withdrawn Tolazamide Garenoxacin may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide Garenoxacin may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Tolfenamic Acid Tolfenamic Acid may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Tolmetin Tolmetin may increase the neuroexcitatory activities of Garenoxacin. Approved Trastuzumab Trastuzumab may increase the cardiotoxic activities of Garenoxacin. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Garenoxacin. Approved, Vet Approved Tribenoside Tribenoside may increase the neuroexcitatory activities of Garenoxacin. Experimental Triptolide Triptolide may increase the neuroexcitatory activities of Garenoxacin. Investigational Trolamine salicylate Trolamine salicylate may increase the neuroexcitatory activities of Garenoxacin. Approved Tromethamine Tromethamine can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ulobetasol The risk or severity of adverse effects can be increased when Ulobetasol is combined with Garenoxacin. Approved Valaciclovir The metabolism of Valaciclovir can be decreased when combined with Garenoxacin. Approved, Investigational Valdecoxib Valdecoxib may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational, Withdrawn Valproic Acid The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Valproic Acid. Approved, Investigational Varenicline The serum concentration of Varenicline can be increased when it is combined with Garenoxacin. Approved, Investigational Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Garenoxacin. Approved Venlafaxine The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Garenoxacin. Approved Warfarin Garenoxacin may increase the anticoagulant activities of Warfarin. Approved Zaltoprofen Zaltoprofen may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational Zileuton Zileuton may increase the neuroexcitatory activities of Garenoxacin. Approved, Investigational, Withdrawn Zinc acetate Zinc acetate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Zinc chloride Zinc chloride can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Zinc oxide Zinc oxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Zomepirac Zomepirac may increase the neuroexcitatory activities of Garenoxacin. Withdrawn - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- ChemSpider
- 110579
- ChEBI
- 131716
- ChEMBL
- CHEMBL215303
- Wikipedia
- Garenoxacin
- ATC Codes
- J01MA19 — Garenoxacin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0232 mg/mL ALOGPS logP 1.71 ALOGPS logP 1.62 ChemAxon logS -4.3 ALOGPS pKa (Strongest Acidic) 6.05 ChemAxon pKa (Strongest Basic) 8.88 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 78.87 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 110.37 m3·mol-1 ChemAxon Polarizability 42.39 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Quinoline carboxylic acids
- Direct Parent
- Quinoline carboxylic acids
- Alternative Parents
- Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Isoindolines / Isoindoles / Aralkylamines / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Amino acids show 10 more
- Substituents
- Quinoline-3-carboxylic acid / Dihydroquinolone / Dihydroquinoline / Isoindoline / Isoindole / Isoindole or derivatives / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Aralkylamine / Benzenoid show 24 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
Drug created on March 19, 2008 10:14 / Updated on August 15, 2018 13:34